BerGenBio ASA
7BG0
Company Profile
Business description
BerGenBio ASA is a clinical-stage biopharmaceutical Company focused on developing novel medicines for aggressive diseases. The company’s clinical asset, bemcentinib, targeting the receptor tyrosine kinase AXL, is currently in development in a Ph1b/2a study in 1L STK 11 mutated NSCLC and preclinical development for severe respiratory infections.
Contact
Mollendalsbakken 9
Bergen5009
NORT: +47 55961159
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
15
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,149.90 | 8.80 | -0.11% |
| CAC 40 | 8,042.95 | 51.25 | -0.63% |
| DAX 40 | 22,891.68 | 107.47 | -0.47% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,646.79 | 55.20 | -0.63% |
| HKSE | 23,658.45 | 31.27 | -0.13% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,718.50 | 41.44 | 0.11% |
| NZX 50 Index | 12,102.92 | 10.62 | -0.09% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,927.20 | 4.00 | -0.05% |
| SSE Composite Index | 3,369.70 | 4.87 | 0.14% |